Sustained correction of OTC deficiency in spfash mice using optimized self-complementary AAV2/8 vectors
Open Access
- 18 August 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Gene Therapy
- Vol. 19 (4), 404-410
- https://doi.org/10.1038/gt.2011.111
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Intellectual, Adaptive, and Behavioral Functioning in Children With Urea Cycle DisordersPediatric Research, 2009
- Potential of AAV vectors in the treatment of metabolic diseaseGene Therapy, 2008
- The role of liver transplantation in urea cycle disordersMolecular Genetics and Metabolism, 2004
- Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transferMolecular Genetics and Metabolism, 2003
- Alternative pathway therapy for urea cycle disorders: Twenty years laterThe Journal of Pediatrics, 2001
- Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiencyJournal of Inherited Metabolic Disease, 1998
- Adenovirus-Mediated in Vivo Gene Transfer Rapidly Protects Ornithine Transcarbamylase-Deficient Mice from an Ammonium ChallengePediatric Research, 1997
- Prolonged Metabolic Correction in Adult Ornithine Transcarbamylase-deficient Mice with Adenoviral VectorsPublished by Elsevier BV ,1996
- MHC class I-cestricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenovirusesImmunity, 1994
- Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.Proceedings of the National Academy of Sciences of the United States of America, 1994